The GLAMM1 Study - Global Access to Myeloma Medications: Potential Barriers to Chimeric Antigen Receptors (CART) and T-Cell-Engaging Bispecific Antibodies (TCE) Globally

Category Primary study
JournalTransplantation and Cellular Therapy
Year 2024
This article has no abstract
Epistemonikos ID: 78ed1be0fc99df9ffe5100025d07b3f09002e863
First added on: Feb 17, 2025